Nyxoah SA (NASDAQ:NYXH) Stock Short Interest Report for October

Nyxoah SA (NASDAQ:NYXH – Get Free Report) saw a large increase in short interest during the month of October. As of October 30th, there was short interest totaling 331,332 shares, an increase of 55.1% from the October 15th total of 213,619 shares. Based on an average daily volume of 337,038 shares, the days-to-cover ratio is currently 1.0 days. Approximately 0.9% of the company’s stock are sold short.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on the stock. Oppenheimer set a $4.00 price objective on shares of Nyxoah in a research note on Thursday, August 6th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Nyxoah in a report on Tuesday. Robert W. Baird set a $2.31 target price on shares of Nyxoah in a research report on Thursday, August 6th. Wall Street Zen upgraded Nyxoah from a “sell” rating to a “hold” rating in a report on Saturday, November 7th. Finally, Cantor Fitzgerald reduced their price target on Nyxoah to $3.00 and set an “overweight” rating for the company in a research report on Tuesday, October 27th. Two equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Nyxoah presently has a consensus rating of “Hold” and a consensus target price of $3.55.

View Our Latest Analysis on Nyxoah

Nyxoah Stock Down 4.1%

Shares of Nyxoah stock opened at $0.86 on Thursday. The stock has a market capitalization of $33.45 million, a P/E ratio of -0.44 and a beta of 1.80. The company has a quick ratio of 2.08, a current ratio of 2.19 and a debt-to-equity ratio of 0.53. The stock has a 50 day moving average price of $1.16 and a two-hundred day moving average price of $2.26. Nyxoah has a 12-month low of $0.80 and a 12-month high of $5.39.

Nyxoah (NASDAQ:NYXH – Get Free Report) last released its quarterly earnings results on Thursday, November 5th. The company reported ($0.20) EPS for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.04. Nyxoah had a negative net margin of 313.03% and a negative return on equity of 153.98%. The company had revenue of $10.39 million for the quarter, compared to analyst estimates of $11.45 million. Equities analysts expect that Nyxoah will post -1.26 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the company. Goldman Sachs Group Inc. bought a new stake in Nyxoah during the third quarter valued at about $30,000. AIGH Capital Management LLC increased its stake in shares of Nyxoah by 0.7% in the third quarter. AIGH Capital Management LLC now owns 14,632,880 shares of the company’s stock worth $20,193,000 after purchasing an additional 98,000 shares during the period. Integrated Wealth Concepts LLC bought a new position in shares of Nyxoah in the second quarter worth about $169,000. IFP Advisors Inc increased its stake in shares of Nyxoah by 35.6% in the second quarter. IFP Advisors Inc now owns 118,426 shares of the company’s stock worth $200,000 after purchasing an additional 31,061 shares during the period. Finally, Readystate Asset Management LP acquired a new position in shares of Nyxoah during the 2nd quarter worth about $351,000.

Nyxoah Company Profile

(Get Free Report)

Nyxoah is a medical technology company focused on treatments for obstructive sleep apnea (OSA), a condition in which breathing repeatedly stops or becomes shallow during sleep. The company develops implantable neurostimulation systems for patients who cannot use or do not benefit from conventional therapies such as continuous positive airway pressure. Its lead product, the Genio system, stimulates the hypoglossal nerve to help keep the tongue from obstructing the airway during sleep. The system uses an implanted stimulator and an external wearable component, and is designed to stimulate both sides of the nerve.

See Also

Receive News & Ratings for Nyxoah Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nyxoah and related companies with MarketBeat.com's FREE daily email newsletter.